Kaken Pharmaceutical Co., Ltd. (KKPCF)

Market Cap	1.01B -5.0%
Revenue (ttm)	482.58M -18.9%
Net Income	-24.44M
EPS	-0.64
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	1.23 (4.75%)
Ex-Dividend Date	Mar 30, 2026

Volume	n/a
Average Volume	n/a
Open	26.00
Previous Close	26.00
Day's Range	26.00 - 26.00
52-Week Range	23.65 - 28.12
Beta	0.07
RSI	60.56
Earnings Date	May 13, 2026

About Kaken Pharmaceutical

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surger...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1917
• Employees: 1,126
• Stock Exchange: OTCMKTS
• Ticker Symbol: KKPCF

Financial Performance

In fiscal year 2026, Kaken Pharmaceutical's revenue was 76.87 billion, a decrease of -18.25% compared to the previous year's 94.04 billion. Earnings were 2.14 billion, a decrease of -84.63%.

Financial numbers in JPY